Safety and clinical performance of the magnesium bioresorbable coronary stent (Freesolve) in the treatment of subjects with long de novo lesions in native coronary arteries: BIOMAG-LL
Zusammenfassung der Studie
This clinical trial will be conducted at 20 sites in Germany, Switzerland, Spain, Poland, Latvia, and Italy. It is planned to include 100 patients. After patients have given their consent to participate in the study, a vascular assistance device will be used. Follow-up clinical examinations will be performed at 1, 6, and 12 months, and then at 36 and 60 months after the intervention. In a smaller group of study participants, after giving their consent, the concentration of the drug released by the bioresorbable stent Freesolve will be measured. Blood samples will be used to measure the amount of drug released by the bioresorbable stent present in the blood at different times after the implantation of Freesolve in the artery. This is called pharmacokinetic evaluation. As part of the pharmacokinetic evaluation, additional blood samples will be taken before implantation and at 10 minutes, 30 minutes, and 1, 2, 3, 4, 6, 12, 24, 48, and 72 hours, as well as 7 days after the implantation of Freesolve.
(BASEC)
Untersuchte Intervention
In BIOMAG-LL, an extension of the size range of Freesolve (scaffold lengths of 35 and 40 mm) will be studied. The aim of the study is to evaluate the safety and clinical performance of Freesolve 35 and 40 mm in de novo coronary lesions up to 38 mm in length. Patients with clinical symptoms are referred to the investigation center for diagnostic testing. Patients who have agreed to participate and received Freesolve (35 mm and 40 mm) will be followed up at 30 days, 1, 6, 12 months, and after 36 and 60 months post-procedure. A pharmacokinetic evaluation will also be conducted in a small group of patients who have given additional consent.
(BASEC)
Untersuchte Krankheit(en)
Coronary arteries (blood vessels in the heart) may have a narrowing that can require treatment. This narrowing can be caused by deposits on the walls of the arteries (atherosclerosis). As a result, the heart does not receive enough oxygen and nutrients, which impairs heart function. This condition is called coronary artery stenosis and can be the cause of clinical symptoms.
(BASEC)
1. Subjects with a maximum of two unique lesions in two distinct coronary arteries, which must be de novo lesions and can each be covered by a single device. 2. Reference vessel diameter between 2.7 and 4.2 mm based on visual estimation, depending on the size of the scaffold used. 3. Target lesion length > 28 and ≤ 38 mm based on visual estimation, depending on the size of the scaffold used. (BASEC)
Ausschlusskriterien
1. The subject is pregnant and/or breastfeeding or intends to become pregnant during the study duration. 2. The subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with ST-segment elevation myocardial infarction (STEMI) less than 72 hours prior to the reference procedure. 3. Known allergies: to aspirin, P2Y12 inhibitors, heparin and bivalirudin, sirolimus (or similar drugs), poly L-lactide, or scaffold material (magnesium, aluminum, tantalum). (BASEC)
Studienstandort
Genf
(BASEC)
Sponsor
BIOTRONIK AG Ackerstrasee 6, 8180 Bülach, Switzerland
(BASEC)
Kontakt für weitere Auskünfte zur Studie
Kontaktperson Schweiz
Juan Fernando Iglesias
+41 (0)79 347 48 49
juanfernando.iglesias@clutterhug.chHopitaux Universitaires de Genève
(BASEC)
Wissenschaftliche Auskünfte
nicht verfügbar
Name der bewilligenden Ethikkommission (bei multizentrischen Studien nur die Leitkommission)
Ethikkommission Genf
(BASEC)
Datum der Bewilligung durch die Ethikkommission
05.03.2026
(BASEC)
ICTRP Studien-ID
nicht verfügbar
Offizieller Titel (Genehmigt von der Ethikkommission)
BIOTRONIK – Safety and Clinical Performance of the Drug Eluting Resorbable MAGnesium Scaffold (Freesolve) in the Treatment of Subjects with Long de Novo Lesions in Native Coronary Arteries: BIOMAG-LL (BASEC)
Wissenschaftlicher Titel
nicht verfügbar
Öffentlicher Titel
nicht verfügbar
Untersuchte Krankheit(en)
nicht verfügbar
Untersuchte Intervention
nicht verfügbar
Studientyp
nicht verfügbar
Studiendesign
nicht verfügbar
Ein-/Ausschlusskriterien
nicht verfügbar
nicht verfügbar
Primäre und sekundäre Endpunkte
nicht verfügbar
nicht verfügbar
Registrierungsdatum
nicht verfügbar
Einschluss des ersten Teilnehmers
nicht verfügbar
Sekundäre Sponsoren
nicht verfügbar
Weitere Kontakte
nicht verfügbar
Sekundäre IDs
nicht verfügbar
Angaben zur Verfügbarkeit von individuellen Teilnehmerdaten
nicht verfügbar
Weitere Informationen zur Studie
nicht verfügbar
Ergebnisse der Studie
Zusammenfassung der Ergebnisse
nicht verfügbar
Link zu den Ergebnissen im Primärregister
nicht verfügbar